VYNE Therapeutics Inc. · NASDAQ:VYNE

VYNE Therapeutics — B&T Cell-Mediated Autoimmune Disease Drug Development Conference 2022

35 slides from VYNE Therapeutics's conference presentation, Jul 27, 2022

  1. Slide 1: The InhiBET Platform

    The InhiBETTM Platform Bromodomain & End Terminal (BET) Inhibitors in Autoimmune Disease Iain Stuart, Ph.D Chief Scientific Officer B&T Cell-Mediated Autoimmune Disease Drug Development Conference, July 27, 2022 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the development of VYNE’s product candidates, the timing of its clinical trials and regulato

  3. Slide 3: Bromodomain and end terminal proteins: Epigenetic enablers of transcription

    Bromodomain and end terminal proteins: Epigenetic enablers of transcription Domain structure of human BET proteins Functional binding domains chromatin chromatin enzyme interaction interaction interaction interaction complex P-TEFb P-TEFb binding cyclin T1 cyclin T1 cdk9 cdk9 • The bromodomain famil

  4. Slide 4: BET Proteins Play a Key Role in Regulation of Inflammatory and Oncogenic Genes

    BET Proteins Play a Key Role in the Regulation of Inflammatory and Oncogenic Genes involved in Several Diseases BET proteins bind to histones in chromatin BRD4 by “reading” acetylated lysine motifs on N- terminus of histone tails and recruit co- regulatory complexes: N-terminal of histones Pro-infla

  5. Slide 5: How BET Proteins Influence Transcriptional Machinery

    How BET Proteins Influence Transcriptional Machinery Role of BET proteins in Pro-Inflammatory Cytokine Production in Autoimmune Diseases Pro-inflammatory cytokines Cytokines bind to 1 cytokine receptors Activation of 2 cytokine NF-κβ kinase complex translation 6 Nuclear 3 translocation BRD4 4 Recrui

  6. Slide 6: BET Inhibitors Block BD1/BD2 Binding to Acetylated Lysines

    BET Inhibitors Block BD1/BD2 Binding to Acetylated Lysines and Stall Pro-inflammatory Protein Transcription Pro-inflammatory cytokines cytokines 5 1 BET INHIBITOR Binds BD1 and/or BD2 of BRD4 protein making it 4 unable recognize acetylated cytokine histones & recruit translation transcription factor

  7. Slide 7: BET inhibitor biology – what have we learned?

    BET inhibitor biology – what have we learned? Bromodomain functionality • Each BRD bromodomain plays distinct roles transcription regulation – they don’t do the same job - Steady-state gene expression primarily requires BD1. - Rapid increase of gene expression induced by inflammatory stimuli require

  8. Slide 8: InhiBET BET Inhibitor Platform Overview

    InhiBET™ BET Inhibitor Platform Overview Small molecule pan-BD and BD2-selective BET inhibitors VYN201 VYN202 Locally administered Pan-BD BET inhibitor Oral BD2-selective BET inhibitor Designed to address diseases involving Designed to selectively bind to BD2 and is multiple, diverse inflammatory ce

  9. Slide 9: VYN202

    VYN202 Orally available BD2 selective BET inhibitor

  10. Slide 10: VYN202 Program Highlights & Molecular Profile

    VYN202 Program Highlights & Molecular Profile VYN202 is an oral BET inhibitor designed to selectively bind to BD2 and is being developed for major immuno-inflammatory diseases Potential Target Market1: Potency vs. BD2 • Immuno-inflammatory indications such as rheumatoid arthritis, systemic lupus ery

  11. Slide 11: VYN201

    VYN201 Locally administered pan-BD BET inhibitor Non-clinical efficacy program

  12. Slide 12: VYN201 Pre-Clinical Efficacy Model Evaluations

    VYN201 Pre-Clinical Efficacy Model Evaluations Program designed to investigate the targeted administration of a “soft drug” pan-BD BET inhibitor to maximize local effect and minimize systemic exposure Indication/area Model Administration Route Status Th17 autoimmune diseases IMI-induction mouse mode

  13. Slide 13: VYN201 Psoriasis murine model (topical)

    VYN201 Psoriasis murine model (topical)

  14. Slide 14: Comparable Efficacy to Superpotent Steroid Clobetasol in Murine Model

    VYN201: Comparable Efficacy to Superpotent Steroid Clobetasol in a TH17-Mediated Murine Inflammation Model; Potential for Greater Tolerability Dorsal depilated BALB-C mice were dosed topically for 14 days with 100mg topical IMI cream (Day 1-7: induction phase, Day 8- 14: treatment phase). N=4 animal

  15. Slide 15: Normal Skin Physiology Suggests VYN201 Well Tolerated

    VYN201: Normal Skin Physiology in TH17-Mediated Murine Inflammation Model Suggests VYN201 Well Tolerated (Day 7) VYN201 Vehicle VYN201 0.1% Clobetasol Cream 0.05% • No appreciable improvement in • Substantial resolution of clinical signs • Substantial resolution of clinical signs clinical signs • Sk

  16. Slide 16: VYN201 Reduced Expression of Key Pro-Inflammatory Proteins in Human Tissue

    VYN201 Significantly Reduced Expression of Several Key Pro-Inflammatory Proteins Relevant to Th17-mediated Autoimmune Diseases in Human Tissue1 >95% Inhibition seen with assays for IL-36γ & -99.5% LP-10 120 Percent inhibition (IL-17α) 100 Interleukin 36-gamma 80 60 IL36γ is implicated in upregulatin

  17. Slide 17: VYN201 Rheumatoid Arthritis murine model (intra-articular)

    VYN201 Rheumatoid Arthritis murine model (intra-articular)

  18. Slide 18: CAIA Mouse Model of Arthritis – Paw Thickness

    VYN201: CAIA Mouse Model of Arthritis – Paw Thickness Marked inhibition of paw thickening/swelling Inflammatory arthritis was induced in BALB/C mice using a mixture of four arthritogenic MAbs by IV injection at Day 0 and was further challenged with an LPS IV injection at Day 4 (N=7/treatment group).

  19. Slide 19: CAIA Mouse Model of Arthritis – Arthritis Score

    VYN201: CAIA Mouse Model of Arthritis – Arthritis Score Demonstrated dose dependent reduction in disease severity 3.50 VYN201 VYN201 VYN201 Vehicle IA 10mg/kg IA 1mg/kg IA Clear dose-response demonstrated between VYN201 VYN201 Dexamethasone 3.00 0.1mg/kg IA 0.01 mg/kg IA 1mg/kg IP VYN201-treated gro

  20. Slide 20: CAIA Mouse Model of Arthritis – Systemic Impact

    VYN201: CAIA Mouse Model of Arthritis – Systemic Impact Demonstrated localized effect 2.00 Paw Thickness VYN201 VYN201 VYN201 VYN201 Vehicle IA 10mg/kg IA 1mg/kg IA 0.1mg/kg IA 1.50 VYN201 Dexamethasone Dexamethasone 0.01 mg/kg IA 1mg/kg IP 1mg/kg IA Δ untreated - treated leg Paw thickness (mm) 1.00

  21. Slide 21: CAIA Mouse Model of Arthritis – Histopathology

    VYN201: CAIA Mouse Model of Arthritis – Histopathology Joint histopathology confirmed arthritis clinical scoring & local effect Inflammation marked with asterisk; damage to bone marked with a blue arrow; inflammatory cells and cellular debris in the joint space marked with red arrow; damage to carti

  22. Slide 22: VYN201 Anti-fibrosis/scarring murine model (topical)

    VYN201 Anti-fibrosis/scarring murine model (topical)

  23. Slide 23: Demonstrated Anti-Fibrotic Activity in Murine Skin Healing Model

    VYN201: Demonstrated Anti-Fibrotic Activity without Delay in Healing Time in Murine Skin Healing Model Female hairless mice (n=4/group) had two identical 10mm incisions made either side of the flank. Animals were topically dosed 1X daily with 100mg VYN201 vehicle, VYN201 1% or a hydroalcoholic gel*

  24. Slide 24: Little Evidence of Residual Swelling and Macular Wound Appearance

    VYN201: Little Evidence of Residual Swelling and Macular Wound Appearance in Murine Skin Healing Model VYN201 Vehicle VYN201 1% Hydroalcoholic gel • Still evidence of minor swelling • Little evidence of residual swelling • Moderate swelling clearly evident at around incision sites • Wound appears mo

  25. Slide 25: VYN201 Idiopathic pulmonary fibrosis murine model (intra-nasal)

    VYN201 Idiopathic pulmonary fibrosis murine model (intra-nasal)

  26. Slide 26: Bleomycin-induced mouse model of idiopathic pulmonary fibrosis

    VYN201: Bleomycin-induced mouse model of idiopathic pulmonary fibrosis Histopathology Images Lung fibrosis is induced in C57bl/6 mice using bleomycin at a dose of 4U/kg once daily by intranasal administration (N=10/treatment group). VYN201 treatment groups received nebulized, intra-nasal doses at 0,

  27. Slide 27: VYN201 Ex vivo human skin explant vitiligo model (topical)

    VYN201 Ex vivo human skin explant vitiligo model (topical)

  28. Slide 28: Human Tissue Model of Vitiligo – Inhibition of MMP9

    VYN201: Human Tissue Model of Vitiligo – Demonstrated Inhibition of MMP9 Reconstituted human epithelial (RHE) skin cultures were treated with a TNF-α and IFN-ɣ cytokine cocktail to induce a vitiligo phenotype melanocytorrhagy (loss of melanocyte), upregulation of MMP9 and soluble E-cadherin). 24hr p

  29. Slide 29: Human Tissue Model of Vitiligo – Reduction of Soluble E-cadherin

    VYN201: Human Tissue Model of Vitiligo – Reduction of Soluble E-cadherin 800 700 600 • Stimulated and vehicle-treated RHE (% untreated unstimulated CTL) 500 422 488 demonstrated a significant Soluble E-cadherin upregulation of soluble E-cadherin, 400 359 relative to unstimulated control 328 300 • VY

  30. Slide 30: Human Tissue Model of Vitiligo – Effect on Melanocyte Retention

    VYN201: Human Tissue Model of Vitiligo – Effect on Melanocyte Retention • Stimulated and vehicle-treated RHE 700 demonstrated a significant loss in melanin content, relative to Relative melanin content in basal layers (% relative to the 498 600 367 unstimulated control 500 • VYN201 substantially pre

  31. Slide 31: Human Tissue Model of Vitiligo - Histology

    VYN201: Human Tissue Model of Vitiligo - Histology Micrographic images of TRV immuno-stained induced RHE specimens demonstrating the preservation of melanocytes in the basal layer of samples treated with VYN201 1% Melanocyte migration Basal layer Retention of melanocytes at the basal layer Unstimula

  32. Slide 32: Human Tissue Model of Vitiligo – Gene regulation

    VYN201: Human Tissue Model of Vitiligo – Gene regulation Transcriptome volcano plots of genes relevant to vitiligo (preliminary findings) Stimulated control Stimulated and VYN201 1% treated Basal layer Significant upregulation of cytokines IL6, IL1α and β and TNF Significant downregulation of cytoki

  33. Slide 33: First in Human Phase 1 Study Design in Non-Segmental Vitiligo

    VYN201: First in Human Phase 1 Study Design in Non-Segmental Vitiligo* Phase 1a/b design comprising of: Phase 1a Part A single ascending / multiple ascending dose cohort in healthy volunteer participants for up to 2 weeks of once daily treatment. • Primary objective is to identify safe starting dose

  34. Slide 34: Targeted Clinical Milestones through 2023

    Targeted Clinical Milestones through 2023 Driving Pipeline to Proof-of-Concept Target Candidate Selection Preclinical Clinical Trials Near-Term Catalysts FMX114 Phase 1b: Completed (tofacitinib/fingolimod gel) Phase 1b/2a Phase 2a: Enrollment Complete; TLR expected Mild-to-moderate Atopic end of Jul

  35. Slide 35: Thank you!

    Thank you! eV YNE’

VYNE Therapeutics — B&T Cell-Mediated Autoimmune Disease Drug Development Conference 2022 on 6ix